Key facts
- Aria CV’s last known valuation is $68.6M (Aug 2025).
- It has raised $50.2M across 5 recorded rounds; the latest was Seed Round ($1.4M) in Aug 2025.
- Notable investors include MedTech Innovator, Samothrace Partners, Angel Physicians Fund, BioStar Capital, Brightstone Venture Capital — 14 tracked in total.
- Aria CV has filed 6 Form Ds with the SEC since 2014, most recently Aug 2025 ($1.4M sold to 39 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Aria CV
Funding rounds
5 roundsAbout Aria CV
Developer of an implantable cardiovascular device designed to treat pulmonary hypertension. The company's devices reduce the workload on the heart and have the potential to enhance both the survival and quality of life of those suffering from pulmonary hypertension, enabling patients to improve outcomes by reducing the workload on the right side of the heart.
- Sector
- Healthcare
- HQ
- Saint Paul, MN, United States
- Founded
- 2010
- Employees
- 19
- Website
- ariacv.com/
- Ownership
- Privately Held (backing)
Aria CV doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aria CV shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aria CV in its N-PORT filings yet. We sweep new filings monthly.